ClinicalTrials.gg
CompletedNCT01718483Updated Jun 8, 2021Results posted

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

A Phase 3 interventional study of SPD489 (Lisdexamfetamine dimesylate) and Placebo in Binge Eating Disorder, sponsored by Shire. Completed at 50 sites in 4 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-08.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
383
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies in Binge-Eating Disorder with a site in United States — 20 open to participants now, 28 under way, 2 of them phase 3. Binge-Eating Disorder · United States.

Enrollment
10th of 112
383 · median 67
Started
2012
with 2 others
Phase 3
15 of 122
2 open now
Registered
31st of 122
by date
Lead sponsor
5 of 122
Shire

Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 10th largest by enrollment of the 112 interventional ones that give a count, is one of 3 that started in 2012, is one of 15 in phase 3, and was the 31st registered.

Binge-Eating Disorder

233 studies on the registry are indexed under Binge-Eating Disorder; 52 are open to participants now.

Browse Binge-Eating Disorder studies →

Open to participants now

20 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 23 (68%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Binge-Eating Disorder with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to demonstrate the efficacy of SPD489 compared with placebo in adults (18 55 years of age inclusive) with moderate to severe Binge Eating Disorder at Visit 8 (Weeks 11 and 12) as measured by the number of binge days (defined as days during which at least 1 binge episode occurs) per week as assessed by clinical interview based on subject diary

03

Conditions studied

  • Binge Eating Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is between 18-55 years of age.
  2. Subject meets the following criteria for a diagnosis of BED:

    Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following: eating, in a discrete period of time (eg, within a 2-hour period) an amount of food that is definitely larger than most people would eat in a similar period of time under similar conditions, and a sense of lack of control over the eating (eg, a feeling that one cannot stop eating or control what or how much one is eating).

    The binge eating episodes are associated with at least 3 of the following: eating much more rapidly than normal; eating until uncomfortably full; eating large amounts of food when not feeling physically hungry; eating alone because of being embarrassed by how much one is eating; feeling disgusted with oneself, depressed, or feeling very guilty after overeating.

    Marked distress regarding binge eating. The binge eating occurs, on average, at least 2 days a week for 6 months. The episodes of binge eating do not occur exclusively during the course of bulimia nervosa or anorexia nervosa.

  3. Subject's BED is of at least moderate severity with subjects reporting at least 3 binge eating days per week for the 14 days prior to the Baseline Visit (Visit 0) as documented in the subject's binge diary. A binge day is a day during which at least 1 binge eating episode occurs.
  4. Female subjects must have a negative serum B HCG pregnancy test and a negative urine pregnancy test.

Exclusion criteria

Exclusion Criteria-

  1. Subject has concurrent symptoms of bulimia nervosa or anorexia nervosa.
  2. Subject is receiving psychotherapy (eg, supportive psychotherapy, cognitive behavior therapy, interpersonal therapy) or weight loss support (eg, Weight Watchers) for BED within 3 months.
  3. Subject has used psychostimulants to facilitate fasting or dieting as a part of their BED within 6 months.
  4. Subject has a lifetime history of psychosis, mania, hypomania, dementia, or ADHD.
  5. Subject is considered a suicide risk in the opinion of the investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the investigator.
  6. Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems.
  7. Subject has recently initiated treatment with a lipid-lowering medication (within the past 3 months).
  8. Subject has a history of moderate or severe hypertension.
  9. Subject is female and pregnant or nursing.
  10. Subjects who have had bariatric surgery, lap bands, duodenal stents, or other procedures for weight loss.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
383 participants (actual)

Study arms

  • Experimental
    SPD489 (Lisdexamfetamine dimesylate)

    Drug: SPD489 (Lisdexamfetamine dimesylate)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 50 or 70 mg administered orally, once-daily for up to 12 weeks

    Also known as: Vyvanse, Venvanse, LDX

  • DrugPlacebo

    Administered once-daily, orally, for up to 12 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Number of Binge Days Per Week at Visit 8 (Weeks 11-12)

    Binge days defined as days during which at least 1 binge episode occurred. As assessed by clinical interview based on participant binge diary.

    Time frame: Baseline and Visit 8 (Weeks 11-12)

Secondary outcomes

  1. Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores

    CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: Up to 12 weeks

  2. Percentage of Participants With a 4-Week Cessation From Binge Eating

    4-week cessation from binge eating is defined as no binge eating episodes for 28 consecutive days prior to the last study visit.

    Time frame: Up to 12 weeks

  3. Percent Change From Baseline in Body Weight at Week 12

    Time frame: Baseline and Week 12

  4. Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Total Score at Week 12

    The Y-BOCS-BE measures the obsession of binge-eating thoughts and compulsiveness of binge-eating behaviors. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). Total scores range from 0 to 40. Reduction in total score indicates improvement.

    Time frame: Baseline and Week 12

  5. Change From Baseline in Fasting Triglyceride Levels at Up to 12 Weeks

    Time frame: Baseline and Week 12/Early termination (ET)

  6. Change From Baseline In Fasting Total Cholesterol Levels at Up to 12 Weeks

    Time frame: Baseline and Week 12/ET

  7. Change From Baseline in Hemoglobin A1c Levels at Up to 12 Weeks

    Time frame: Baseline and Week 12/ET

  8. Binge Eating Response

    Response is based on the reduction in the number of binge eating episodes. Percentage of participants with response was reported. Responses were categorized as follows: 1-week Cessation = 100% reduction in binge episodes during the preceding 7 days. Marked Reduction = 99% to 75% reduction during the time since the previous visit. Moderate Reduction = 74% to 50% reduction during the time since the previous visit. Negative to Minimal Reduction = \<50% reduction during the time since the previous visit.

    Time frame: Week 12/ET

  9. Change From Baseline in the Number of Binge Episodes Per Week at Visit 8 (Weeks 11-12)

    Time frame: Baseline and Visit 8 (Weeks 11-12)

  10. Change From Baseline in Eating Inventory Scores at Week 12

    The Eating Inventory also known as the Three-Factor Eating Questionnaire is a 51-item self-reported questionnaire intended to assess 3 dimensions of eating behavior. There are 36 true/false items, 14 items on a 4-point Likert scale (1=eat rarely to 4=always), and 1 item on a 6-point Likert scale (1=eat whatever you want to 6=constantly limiting food intake). Cognitive Restraint score ranges from 0-21. Hunger score ranges from 0-14. Disinhibition score ranges from 0-16. Higher scores denote higher levels of restrained eating, disinhibited eating and predisposition to hunger.

    Time frame: Baseline and Week 12

  11. Change From Baseline in Binge Eating Scale (BES) Score at Week 12

    The BES is a self-reported questionnaire containing 16 items designed to assess behavioral, affective, and attitudinal components of the subjective experience of binge eating. Each item is assessed based on 1 of 4 responses, with 1 denoting that a participant has greater control over eating behavior and 4 denoting that a participant had less control over eating behavior. A total score (sum of the 16 items) may range from 16-64. A lower score indicates greater control over eating behavior.

    Time frame: Baseline and Week 12

  12. Change From Baseline in Frontal Systems Behavior (FrSBe) Total Score at Week 12

    The FrSBe is a 46-item self-rating scale designed to measure the neurobehavioral traits associated with the 3 primary regions of the prefrontal cortex. Participants were asked to indicate the frequency with which they have engaged in certain behaviors using a rating scale from "1" (almost never) to "5" (almost always). Summary scores were calculated and converted to t-score. A decrease from baseline in FrSBe total score represents improvement.

    Time frame: Baseline and Week 12

  13. EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Mobility

    Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various mobility conditions were reported.

    Time frame: Up to 12 weeks

  14. EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Self-Care

    Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various self-care conditions were reported.

    Time frame: Up to 12 weeks

  15. EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Usual Activities

    Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various usual activities conditions were reported.

    Time frame: Up to 12 weeks

  16. EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Pain/Discomfort

    Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various pain/discomfort conditions were reported.

    Time frame: Up to 12 weeks

  17. EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Anxiety/Depression

    Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various anxiety/depression conditions were reported.

    Time frame: Up to 12 weeks

  18. Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale. Number of participants with suicidal ideation and suicidal behavior were reported.

    Time frame: Up to 12 weeks

  19. Amphetamine Cessation Symptom Assessment (ACSA) Total Score

    ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

    Time frame: Up to 12 weeks

07

Results

Posted Jul 21, 2014

Participant flow

Participants were recruited between 12-Nov-2012 and 19-June-2013 and locations included medical clinics \& research centers.

Participant flow — Overall Study
MilestonePLACEBOSPD489
Started191192
Treated187192
Completed157158
Not completed3434
Withdrew: Withdrawal by subject1412
Withdrew: Adverse event512
Withdrew: Lost to follow-up83
Withdrew: Protocol violation42
Withdrew: Other14
Withdrew: Pregnancy11
Withdrew: Lack of efficacy10

Outcome measures

PrimaryChange From Baseline in the Number of Binge Days Per Week at Visit 8 (Weeks 11-12)

Binge days defined as days during which at least 1 binge episode occurred. As assessed by clinical interview based on participant binge diary.

Time frame:
Baseline and Visit 8 (Weeks 11-12)
Reported as:
Least squares mean · Binge days per week
Change From Baseline in the Number of Binge Days Per Week at Visit 8 (Weeks 11-12)
Binge days per weekPLACEBOSPD489
Change From Baseline in the Number of Binge Days Per Week at Visit 8 (Weeks 11-12)-2.51 ± 0.125-3.87 ± 0.124
Statistical analysis
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 · Least squares mean difference: -1.35 · 95% CI -1.70 to -1.01
SecondaryPercentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores

CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores
percentage of participantsPLACEBOSPD489
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores47.3 (40.1 to 54.5)82.1 (76.7 to 87.6)
Statistical analysis
  • PLACEBO vs SPD489 · Chi-squared · p = <0.001
SecondaryPercentage of Participants With a 4-Week Cessation From Binge Eating

4-week cessation from binge eating is defined as no binge eating episodes for 28 consecutive days prior to the last study visit.

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a 4-Week Cessation From Binge Eating
percentage of participantsPLACEBOSPD489
Percentage of Participants With a 4-Week Cessation From Binge Eating14.1 (9.1 to 19.2)40.0 (33.0 to 47.0)
Statistical analysis
  • PLACEBO vs SPD489 · Chi-squared · p = <0.001
SecondaryPercent Change From Baseline in Body Weight at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight at Week 12
percent changePLACEBOSPD489
Percent Change From Baseline in Body Weight at Week 120.11 ± 0.295-6.25 ± 0.292
Statistical analysis
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 · Least squares mean difference: -6.35 · 95% CI -7.17 to -5.54
SecondaryChange From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Total Score at Week 12

The Y-BOCS-BE measures the obsession of binge-eating thoughts and compulsiveness of binge-eating behaviors. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). Total scores range from 0 to 40. Reduction in total score indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Total Score at Week 12
units on a scalePLACEBOSPD489
Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Total Score at Week 12-8.28 ± 0.550-15.68 ± 0.546
Statistical analysis
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 · Least squares mean difference: -7.40 · 95% CI -8.93 to -5.88
SecondaryChange From Baseline in Fasting Triglyceride Levels at Up to 12 Weeks
Time frame:
Baseline and Week 12/Early termination (ET)
Reported as:
Least squares mean · millimole per liter (mmol/L)
Change From Baseline in Fasting Triglyceride Levels at Up to 12 Weeks
millimole per liter (mmol/L)PLACEBOSPD489
Change From Baseline in Fasting Triglyceride Levels at Up to 12 Weeks0.122 ± 0.0405-0.077 ± 0.0393
Statistical analysis
  • PLACEBO vs SPD489 · ANCOVA · p = <0.001 · Least squares mean difference: -0.199 · 95% CI -0.310 to -0.088
SecondaryChange From Baseline In Fasting Total Cholesterol Levels at Up to 12 Weeks
Time frame:
Baseline and Week 12/ET
Reported as:
Least squares mean · mmol/L
Change From Baseline In Fasting Total Cholesterol Levels at Up to 12 Weeks
mmol/LPLACEBOSPD489
Change From Baseline In Fasting Total Cholesterol Levels at Up to 12 Weeks-0.094 ± 0.0435-0.305 ± 0.0422
Statistical analysis
  • PLACEBO vs SPD489 · ANCOVA · p = <0.001 · Least squares mean difference: -0.211 · 95% CI -0.330 to -0.092
SecondaryChange From Baseline in Hemoglobin A1c Levels at Up to 12 Weeks
Time frame:
Baseline and Week 12/ET
Reported as:
Least squares mean · Percent hemoglobin
Change From Baseline in Hemoglobin A1c Levels at Up to 12 Weeks
Percent hemoglobinPLACEBOSPD489
Change From Baseline in Hemoglobin A1c Levels at Up to 12 Weeks0.01 ± 0.016-0.02 ± 0.015
Statistical analysis
  • PLACEBO vs SPD489 · ANCOVA · p = 0.308 · Least squares mean difference: -0.02 · 95% CI -0.07 to 0.02
SecondaryBinge Eating Response

Response is based on the reduction in the number of binge eating episodes. Percentage of participants with response was reported. Responses were categorized as follows: 1-week Cessation = 100% reduction in binge episodes during the preceding 7 days. Marked Reduction = 99% to 75% reduction during the time since the previous visit. Moderate Reduction = 74% to 50% reduction during the time since the previous visit. Negative to Minimal Reduction = \<50% reduction during the time since the previous visit.

Time frame:
Week 12/ET
Reported as:
Number · percentage of participants
Binge Eating Response
percentage of participantsPLACEBOSPD489
1-week cessation26.647.1
Marked Reduction15.231.6
Moderate Reduction17.911.8
Negative to Minimal Reduction40.29.6
Statistical analysis
  • PLACEBO vs SPD489 · Cochran-Mantel-Haenszel · p = <0.001 (Multiplicity is not adjusted for this secondary efficacy endpoint in this study.)
SecondaryChange From Baseline in the Number of Binge Episodes Per Week at Visit 8 (Weeks 11-12)
Time frame:
Baseline and Visit 8 (Weeks 11-12)
Reported as:
Least squares mean · Binge episodes per week
Change From Baseline in the Number of Binge Episodes Per Week at Visit 8 (Weeks 11-12)
Binge episodes per weekPLACEBOSPD489
Change From Baseline in the Number of Binge Episodes Per Week at Visit 8 (Weeks 11-12)-3.49 ± 0.170-5.27 ± 0.168
Statistical analysis
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 (Multiplicity is not adjusted for this secondary efficacy endpoint in this study.) · Least squares mean difference: -1.77 · 95% CI -2.24 to -1.30
SecondaryChange From Baseline in Eating Inventory Scores at Week 12

The Eating Inventory also known as the Three-Factor Eating Questionnaire is a 51-item self-reported questionnaire intended to assess 3 dimensions of eating behavior. There are 36 true/false items, 14 items on a 4-point Likert scale (1=eat rarely to 4=always), and 1 item on a 6-point Likert scale (1=eat whatever you want to 6=constantly limiting food intake). Cognitive Restraint score ranges from 0-21. Hunger score ranges from 0-14. Disinhibition score ranges from 0-16. Higher scores denote higher levels of restrained eating, disinhibited eating and predisposition to hunger.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Eating Inventory Scores at Week 12
units on a scalePLACEBOSPD489
Cognitive Restraint of Eating1.63 ± 0.3313.27 ± 0.329
Disinhibition of Eating-2.12 ± 0.286-6.31 ± 0.285
Perceived Hunger-1.90 ± 0.286-6.60 ± 0.285
Statistical analysis
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 (Multiplicity is not adjusted for this secondary efficacy endpoint in this study.) · Least squares mean difference: 1.65 · 95% CI 0.72 to 2.57
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 (Multiplicity is not adjusted for this secondary efficacy endpoint in this study.) · Least squares mean difference: -4.19 · 95% CI -4.98 to -3.39
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 (Multiplicity is not adjusted for this secondary efficacy endpoint in this study.) · Least squares mean difference: -4.70 · 95% CI -5.49 to -3.91
SecondaryChange From Baseline in Binge Eating Scale (BES) Score at Week 12

The BES is a self-reported questionnaire containing 16 items designed to assess behavioral, affective, and attitudinal components of the subjective experience of binge eating. Each item is assessed based on 1 of 4 responses, with 1 denoting that a participant has greater control over eating behavior and 4 denoting that a participant had less control over eating behavior. A total score (sum of the 16 items) may range from 16-64. A lower score indicates greater control over eating behavior.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Binge Eating Scale (BES) Score at Week 12
units on a scalePLACEBOSPD489
Change From Baseline in Binge Eating Scale (BES) Score at Week 12-8.55 ± 0.763-18.87 ± 0.755
Statistical analysis
  • PLACEBO vs SPD489 · Mixed Models Repeated Measures Analysis · p = <0.001 (Multiplicity is not adjusted for this secondary efficacy endpoint in this study.) · Least squares mean difference: -10.32 · 95% CI -12.43 to -8.21
SecondaryChange From Baseline in Frontal Systems Behavior (FrSBe) Total Score at Week 12

The FrSBe is a 46-item self-rating scale designed to measure the neurobehavioral traits associated with the 3 primary regions of the prefrontal cortex. Participants were asked to indicate the frequency with which they have engaged in certain behaviors using a rating scale from "1" (almost never) to "5" (almost always). Summary scores were calculated and converted to t-score. A decrease from baseline in FrSBe total score represents improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · t-scores
Change From Baseline in Frontal Systems Behavior (FrSBe) Total Score at Week 12
t-scoresPLACEBOSPD489
Change From Baseline in Frontal Systems Behavior (FrSBe) Total Score at Week 12-3.09 ± 0.592-3.40 ± 0.572
Statistical analysis
  • PLACEBO vs SPD489 · ANCOVA · p = 0.706 (Multiplicity is not adjusted for this secondary efficacy endpoint in this study.) · Least squares mean difference: -0.31 · 95% CI -1.93 to 1.31
SecondaryEuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Mobility

Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various mobility conditions were reported.

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Mobility
percentage of participantsPLACEBOSPD489
No problems walking about82.687.2
Slight problems walking about14.010.7
Moderate problems walking about2.82.1
Severe problems walking about0.60
Unable to walk about00
SecondaryEuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Self-Care

Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various self-care conditions were reported.

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Self-Care
percentage of participantsPLACEBOSPD489
No problems washing or dressing89.395.7
Slight problems washing or dressing6.73.2
Moderate problems washing or dressing3.91.1
Severe problems washing or dressing00
Unable to wash or dress00
SecondaryEuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Usual Activities

Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various usual activities conditions were reported.

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Usual Activities
percentage of participantsPLACEBOSPD489
No problems doing usual activities78.087.1
Slight problems doing usual activities14.79.7
Moderate problems doing usual activities6.23.2
Severe problems doing usual activities1.10
Unable to do usual activities00
SecondaryEuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Pain/Discomfort

Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various pain/discomfort conditions were reported.

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Pain/Discomfort
percentage of participantsPLACEBOSPD489
No pain or discomfort64.671.1
Slight pain or discomfort27.520.9
Moderate pain or discomfort7.37.5
Severe pain or discomfort0.60.5
Extreme pain or discomfort00
SecondaryEuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Anxiety/Depression

Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various anxiety/depression conditions were reported.

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Anxiety/Depression
percentage of participantsPLACEBOSPD489
Not anxious or depressed70.272.2
Slightly anxious or depressed19.716.6
Moderately anxious or depressed7.99.1
Severely anxious or depressed2.21.6
Extremely anxious or depressed00.5
SecondaryColumbia-Suicide Severity Rating Scale (C-SSRS)

C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale. Number of participants with suicidal ideation and suicidal behavior were reported.

Time frame:
Up to 12 weeks
Reported as:
Number · participants
Columbia-Suicide Severity Rating Scale (C-SSRS)
participantsPLACEBOSPD489
Suicidal Ideation32
Suicidal behavior00
SecondaryAmphetamine Cessation Symptom Assessment (ACSA) Total Score

ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

Time frame:
Up to 12 weeks
Reported as:
Mean · units on a scale
Amphetamine Cessation Symptom Assessment (ACSA) Total Score
units on a scalePLACEBOSPD489
Amphetamine Cessation Symptom Assessment (ACSA) Total Score7.3 ± 7.745.7 ± 7.37

Adverse events

Collected over From first dose of study drug up to 3 days after the last dose at up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PLACEBO—2/187 (1.1%)67/187 (35.8%)
SPD489—3/192 (1.6%)125/192 (65.1%)
Most frequent serious events
Most frequent serious events
EventPLACEBOSPD489
SyncopeNervous system disorders0/1872/192
Anaphylactic reactionImmune system disorders1/1870/192
Conversion disorderPsychiatric disorders1/1870/192
CholecystitisHepatobiliary disorders0/1871/192
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPLACEBOSPD489
Dry mouthGastrointestinal disorders16/18776/192
InsomniaPsychiatric disorders14/18734/192
HeadacheNervous system disorders17/18726/192
Decreased appetiteMetabolism and nutrition disorders6/18717/192
NauseaGastrointestinal disorders14/18716/192
IrritabilityGeneral disorders13/18716/192
Heart rate increasedInvestigations5/18714/192
AnxietyPsychiatric disorders2/18713/192
Upper respiratory tract infectionInfections and infestations11/1878/192
ConstipationGastrointestinal disorders4/18711/192

Baseline characteristics

Safety Analysis Set was used for Baseline Measures. The Safety Analysis Set was defined as all randomized participants who took at least 1 dose of investigational product and who had at least 1 post-baseline safety assessment completed. Four participants did not receive investigational product, therefore n=379.

Age, Continuous
Age, Continuous(Years)PLACEBOSPD489Total
Mean37.6 ± 10.2138.5 ± 10.438.1 ± 10.3
Age, Customized
Age, Customized(Participants)PLACEBOSPD489Total
<40 years10298200
>=40 years8594179
Sex: Female, Male
Sex: Female, Male(Participants)PLACEBOSPD489Total
Female163165328
Male242751
Region of Enrollment
Region of Enrollment(Participants)PLACEBOSPD489Total
GERMANY213
SPAIN5510
SWEDEN151328
UNITED STATES165173338
08

Study locations

50 sites
  • Birmingham Research Group
    Birmingham, Alabama 35216, United States
  • Clinical Study Centers, LLC
    Little Rock, Arkansas 72211, United States
  • Trimed Clinical Trials
    Corona, California 92880, United States
  • Pharmacology Research Institute
    Encino, California 91316, United States
  • Pharmacology Research Institute
    Los Alamitos, California 90720, United States
  • Pacific Research Partners, LLC
    Oakland, California 94812, United States
  • Research Across America
    Santa Ana, California 92705, United States
  • Western Affiliated Research Institute, Inc.
    Denver, Colorado 80209, United States
  • Gulfcoast Clinical Research
    Fort Myers, Florida 33912, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Fidelity Clinical Research, Inc.
    Lauderhill, Florida 33319, United States
  • Compass Research LLC
    Leesburg, Florida 34748, United States
  • Scientific Clinical Research Inc.
    North Miami, Florida 33161, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • Alexian Brothers Behavioral Health Hospital
    Hoffman Estates, Illinois 60169, United States
  • AMR Baber Research, Inc.
    Naperville, Illinois 60563, United States
  • Goldpoint Clinical Research, LLC
    Indianapolis, Indiana 46260, United States
  • Cypress Medical Research Center, LLC
    Wichita, Kansas 67226, United States
  • McLean Hospital
    Belmont, Massachusetts 02478, United States
  • St. Charles Psychiatric Associates/Midwest Research Group
    Saint Charles, Missouri 63304, United States
  • Center for Psychiatry and Behavioral Medicine, Inc.
    Las Vegas, Nevada 89128, United States
  • Pacific Research for Research and Evaluation
    Albuquerque, New Mexico 87102, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • Community Research
    Cincinnati, Ohio 45227, United States
  • Midwest Clinical Research Center, LLC
    Dayton, Ohio 45417, United States
  • North Star Medical Research
    Middleburg Heights, Ohio 44130, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Oregon Center for Clinical Investigations, Inc.
    Salem, Oregon 97301, United States
  • The Clinical Trials Center, LLC
    Jenkintown, Pennsylvania 19046, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Clinical Trials Research Services, LLC
    Pittsburgh, Pennsylvania 15206, United States
  • Radiant Research, Inc.
    Anderson, South Carolina 29621, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • Future Search Trials
    Austin, Texas 78731, United States
  • Futuresearch Trials of Dallas, L.P.
    Dallas, Texas 75231, United States
  • Grayline Clinical Drug Trials
    Wichita Falls, Texas 76309, United States
  • Radiant Research, Inc.
    Murray, Utah 84123, United States
  • Neuropsychiatric Associates, LLC
    Woodstock, Vermont 05091, United States
  • Charlottesville Medical Research Center, LLC
    Charlottesville, Virginia 22911, United States
  • Alliance Research Group
    Richmond, Virginia 23230, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Dean Foundation for Health, Research and Educations, Inc.
    Middleton, Wisconsin 53562, United States
  • Ernovis GmbH
    Berlin, 10629, Germany
  • Klinische Forschung Dresden GmbH
    Dresden, 01069, Germany
  • Studienzentrum Nordwest, Gemeinschaftspraxis
    Westerstede, 26655, Germany
  • Hospital Universitario Infanta Leonor
    Madrid, 28031, Spain
  • Lakarmottagning Ekdahl & Kronberg
    Malmo, 22152, Sweden
  • Sophiahemmet
    Stockholm, 11486, Sweden
  • Stockholm Center for Eating Disorders
    Stockholm, 11850, Sweden
09

References and documents

Publications

  • McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials. Neuropsychopharmacology. 2016 Apr;41(5):1251-60. doi: 10.1038/npp.2015.275. Epub 2015 Sep 9. PubMed 26346638 ↗
  • Robertson B, Wu J, Fant RV, Schnoll SH, McElroy SL. Assessment of Amphetamine Withdrawal Symptoms of Lisdexamfetamine Dimesylate Treatment for Adults With Binge-Eating Disorder. Prim Care Companion CNS Disord. 2020 Mar 26;22(2):19m02540. doi: 10.4088/PCC.19m02540. PubMed 32237290 ↗
  • Kornstein SG, Bliss C, Kando J, Madhoo M. Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age. J Clin Psychiatry. 2019 Feb 26;80(2):18m12378. doi: 10.4088/JCP.18m12378. PubMed 30817099 ↗
  • Sheehan DV, Gasior M, McElroy SL, Radewonuk J, Herman BK, Hudson J. Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Results from Two Randomized, Placebo-controlled Trials. Innov Clin Neurosci. 2018 Jun 1;15(5-6):22-29. PubMed 30013816 ↗
  • Citrome L, Kando JC, Bliss C. Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies. Neuropsychiatr Dis Treat. 2018 Feb 15;14:537-546. doi: 10.2147/NDT.S158395. eCollection 2018. PubMed 29497297 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2012 to primary completion in Sep 2013, 9 months.

Results were first posted in Jul 2014, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2012
First posted
Oct 31, 2012
StartActual
Nov 26, 2012
Primary completionActual
Sep 25, 2013
CompletionActual
Sep 25, 2013
Results first posted
Jul 21, 2014
Last update
Jun 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01718483
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Oct 31, 2012
Start date
Nov 26, 2012
Primary completion
Sep 25, 2013
Completion
Sep 25, 2013
Results posted
Jul 21, 2014
Last update
Jun 8, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion